Using a systems pharmacology approach and molecular docking, the researchers investigated potential pathways for BXD treatment in the fight against irritable bowel syndrome (IBS) and predicted promising drug targets, such as PTGS2, NOS2, and PRSS1. Here, PRSS1 is linked to irritable bowel syndrome.